584 results on '"Calon, Frédéric"'
Search Results
2. Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary
3. Postsynaptic Protein Shank3a Deficiency Synergizes with Alzheimer's Disease Neuropathology to Impair Cognitive Performance in the 3xTg-AD Murine Model
4. Age-dependent impact of streptozotocin on metabolic endpoints and Alzheimer's disease pathologies in 3xTg-AD mice
5. Aging, sex, metabolic and life experience factors: Contributions to neuro-inflammaging in Alzheimer’s disease research
6. Correction to: Higher angiotensin‑converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer’s disease
7. Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer’s disease
8. Direct and Indirect Effects of Filamin A on Tau Pathology in Neuronal Cells
9. Investigating the plasma-liver-brain axis of omega-3 fatty acid metabolism in mouse knock-in for the human apolipoprotein E epsilon 4 allele
10. Sauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia
11. Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
12. Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons
13. A diet rich in docosahexaenoic acid enhances reactive astrogliosis and ramified microglia morphology in apolipoprotein E epsilon 4-targeted replacement mice
14. Lower GLUT1 and unchanged MCT1 in Alzheimer's disease cerebrovasculature.
15. Strategies in the design and development of (TAR) DNA-binding protein 43 (TDP-43) binding ligands
16. Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease
17. Postmortem lipid abnormalities in the cerebellum of patients with essential tremor
18. High-Fat Diets in Animal Models of Alzheimer’s Disease: How Can Eating Too Much Fat Increase Alzheimer’s Disease Risk?
19. Natural Health Products for Symptomatic Relief of Parkinson’s Disease: Prevalence, Interest, and Awareness
20. Targeting TDP-43 Pathology Alleviates Cognitive and Motor Deficits Caused by Chronic Cerebral Hypoperfusion
21. Plant-based natural products for symptomatic relief of Parkinson’s disease: prevalence, interest, awareness and determinants
22. How nutrients and natural products act on the brain: Beyond pharmacology
23. Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model
24. The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
25. Repeated cold exposures protect a mouse model of Alzheimer's disease against cold-induced tau phosphorylation
26. Dietary intake of branched-chain amino acids in a mouse model of Alzheimer's disease: Effects on survival, behavior, and neuropathology
27. Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer’s disease
28. Sex-dependent alterations in the physiology of entorhinal cortex neurons in old heterozygous 3xTg-AD mice
29. Docosahexaenoic acid prevents cognitive deficits in human apolipoprotein E epsilon 4-targeted replacement mice
30. Altered cerebral insulin response in transgenic mice expressing the epsilon-4 allele of the human apolipoprotein E gene
31. Neuroligin-1 is altered in the hippocampus of Alzheimer’s disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers
32. Impaired thermoregulation and beneficial effects of thermoneutrality in the 3×Tg-AD model of Alzheimer's disease
33. Higher Angiotensin I Converting Enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer’s disease
34. Evidence of Filamin A loss of solubility at the prodromal stage of neuropathologically-defined Alzheimer’s disease
35. Direct and Indirect Effects of Filamin A on Tau Pathology in Neuronal Cells
36. Cerebrovascular insulin receptors are defective in Alzheimer’s disease
37. Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease
38. Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson's disease.
39. eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response
40. The Alzheimer risk factor CD2AP causes dysfunction of the brain vascular network
41. Risk of Neutropenia in Adults Treated with Piperacillin–Tazobactam or Cefazolin: A Retrospective Cohort Study
42. Impact of DHA intake in a mouse model of synucleinopathy
43. Sex and Age Differences in a Progressive Synucleinopathy Mouse Model.
44. Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
45. Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
46. Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
47. Increased insoluble Filamin A concentrations in post-mortem brain tissue during mid-stage Alzheimer’s disease (Neurosymposium 2022 poster)
48. SFN poster
49. Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease
50. Cerebrovascular insulin receptors are defective in Alzheimer's disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.